Cells (Nov 2021)

Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles

  • Heide-Marie Binder,
  • Nicole Maeding,
  • Martin Wolf,
  • André Cronemberger Andrade,
  • Balazs Vari,
  • Linda Krisch,
  • Fausto Gueths Gomes,
  • Constantin Blöchl,
  • Katharina Muigg,
  • Rodolphe Poupardin,
  • Anna M. Raninger,
  • Thomas Heuser,
  • Astrid Obermayer,
  • Patricia Ebner-Peking,
  • Lisa Pleyer,
  • Richard Greil,
  • Christian G. Huber,
  • Katharina Schallmoser,
  • Dirk Strunk

DOI
https://doi.org/10.3390/cells10123321
Journal volume & issue
Vol. 10, no. 12
p. 3321

Abstract

Read online

Acute myeloid leukemia (AML) cells can secrete trophic factors, including extracellular vesicles (EVs), instructing the stromal leukemic niche. Here, we introduce a scalable workflow for purification of immunomodulatory AML-EVs to compare their phenotype and function to the parental AML cells and their secreted soluble factors. AML cell lines HL-60, KG-1, OCI-AML3, and MOLM-14 released EVs with a peak diameter of approximately 80 nm in serum-free particle-reduced medium. We enriched EVs >100x using tangential flow filtration (TFF) and separated AML-derived soluble factors and cells in parallel. EVs were characterized by electron microscopy, immunoblotting, and flow cytometry, confirming the double-membrane morphology, purity and identity. AML-EVs showed significant enrichment of immune response and leukemia-related pathways in tandem mass-tag proteomics and a significant dose-dependent inhibition of T cell proliferation, which was not observed with AML cells or their soluble factors. Furthermore, AML-EVs dose-dependently reduced NK cell lysis of third-party K-562 leukemia targets. This emphasizes the peculiar role of AML-EVs in leukemia immune escape and indicates novel EV-based targets for therapeutic interventions.

Keywords